<DOC>
	<DOC>NCT03015909</DOC>
	<brief_summary>The purpose of this study is to assess the ease of use, preference, and safety after 8 weeks subcutaneous administration of EutropinPen Inj. in patients pretreated with recombinant human growth hormone by reusable device.</brief_summary>
	<brief_title>Evaluation of the Ease of Use, Preference, and Safety of EutropinPen Inj.</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Dwarfism, Pituitary</mesh_term>
	<mesh_term>Kidney Failure, Chronic</mesh_term>
	<mesh_term>Turner Syndrome</mesh_term>
	<mesh_term>Gonadal Dysgenesis</mesh_term>
	<mesh_term>Primary Ovarian Insufficiency</mesh_term>
	<mesh_term>Dwarfism</mesh_term>
	<criteria>Subjects who has been using reusable device growth hormone injection in recent 3 months at least for 6 weeks Subjects who meets the indication of EutropinPen inj. Subjects who has diseases below on screening visit Diabetes Malignant tumor Epiphyseal closure Chronic kidney disease (recieved kidney transplantation) Acute respitory failure</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>